AR127361A2 - Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación - Google Patents

Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación

Info

Publication number
AR127361A2
AR127361A2 ARP220102789A ARP220102789A AR127361A2 AR 127361 A2 AR127361 A2 AR 127361A2 AR P220102789 A ARP220102789 A AR P220102789A AR P220102789 A ARP220102789 A AR P220102789A AR 127361 A2 AR127361 A2 AR 127361A2
Authority
AR
Argentina
Prior art keywords
rna
lipoplex
particles
preparation
pharmaceutical composition
Prior art date
Application number
ARP220102789A
Other languages
English (en)
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of AR127361A2 publication Critical patent/AR127361A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden partículas de lipoplejos y ARN. La presente invención, además, se refiere a los métodos que permiten la preparación de partículas de lipoplejos y ARN de una manera que cumpla con las Buenas Prácticas de Fabricación Industrial. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende: partículas de lipoplejos y ARN que comprenden: ARN que codifica un péptido o una proteína que comprende al menos un epítope, al menos un lípido catiónico y al menos un lípido adicional, en donde la relación de cargas positivas y cargas negativas en las partículas de lipoplejos y ARN es desde 1:2 hasta 1,9:2, o 1,3:2,0, cloruro de sodio a una concentración desde 0 mM hasta 40 mM, un estabilizador, un amortiguador, y un agente quelante.
ARP220102789A 2017-10-20 2022-10-13 Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación AR127361A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762574965P 2017-10-20 2017-10-20

Publications (1)

Publication Number Publication Date
AR127361A2 true AR127361A2 (es) 2024-01-17

Family

ID=63965663

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP180103065A AR113782A1 (es) 2017-10-20 2018-10-19 Preparación y almacenamiento de formulaciones de arn liposomal adecuadas para tratamiento
ARP220102789A AR127361A2 (es) 2017-10-20 2022-10-13 Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP180103065A AR113782A1 (es) 2017-10-20 2018-10-19 Preparación y almacenamiento de formulaciones de arn liposomal adecuadas para tratamiento

Country Status (16)

Country Link
US (3) US11395799B2 (es)
EP (2) EP3858333B1 (es)
JP (3) JP2021500324A (es)
KR (2) KR20250024524A (es)
CN (3) CN114392233A (es)
AR (2) AR113782A1 (es)
AU (2) AU2018350846B2 (es)
BR (1) BR112020007470A2 (es)
CA (1) CA3078292A1 (es)
IL (1) IL273852A (es)
MX (3) MX2020003413A (es)
RU (1) RU2022103533A (es)
SG (1) SG11202002579SA (es)
TW (2) TW202146031A (es)
WO (1) WO2019077053A1 (es)
ZA (1) ZA202001675B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
RU2022103533A (ru) 2017-10-20 2022-03-10 Бионтек Рна Фармасьютикалс Гмбх (Biontech Rna Pharmaceuticals Gmbh) Приготовление и хранение липосомальных РНК-составов, подходящих для терапии
EP3740241A1 (en) * 2018-01-18 2020-11-25 eTheRNA Immunotherapies NV Lipid nanoparticles
WO2020200472A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
JP2023540134A (ja) 2020-09-08 2023-09-21 ジェネンテック， インコーポレイテッド 蠕動式ポンプおよび減衰装置を使用して薬学的組成物を生産するためのシステムおよび方法
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存
US20220218622A1 (en) 2020-10-14 2022-07-14 George Mason Research Foundation, Inc. Ionizable lipids and methods of manufacture and use thereof
CN116669709A (zh) * 2020-11-16 2023-08-29 生物技术公司 包含颗粒和mRNA的药物组合物及其制备和储存的方法
EP4297889A4 (en) * 2021-02-23 2025-01-15 Nature's Toolbox, Inc. ENCAPSULATION OF LIPID DNA PARTICLES (LNP) OF mRNA PRODUCTS
WO2022235853A1 (en) 2021-05-04 2022-11-10 BioNTech SE Immunogen selection
MX2024001243A (es) 2021-07-29 2024-02-13 BioNTech SE Composiciones y metodos para el tratamiento de melanoma.
EP4412591A1 (en) 2021-10-06 2024-08-14 leon-nanodrugs GmbH Method for preparing lipid nanoparticles
CN114601747A (zh) * 2022-03-07 2022-06-10 广州市万千粉丝化妆品有限公司 一种催生蛋白及rna具有延长细胞端粒和增殖的核蛋白端粒酶在化妆品中的应用
IL315396A (en) * 2022-03-08 2024-11-01 Mastery Biotech Co Ltd Pharmaceutical composition including retinoic acid and carbohydrate and use thereof
EP4551247A1 (en) 2022-07-07 2025-05-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Immunogens and methods for inducing an immune response
AU2023342641A1 (en) 2022-09-15 2025-03-27 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
CN116083491A (zh) * 2023-01-05 2023-05-09 上海利康瑞生物工程有限公司 一种阳离子转染试剂组合物及应用
WO2024213740A1 (en) 2023-04-14 2024-10-17 BioNTech SE Vaccine mixing method, syringe and system
WO2025003406A1 (en) 2023-06-29 2025-01-02 BioNTech SE Modular multiplatform system for mrna drug production
WO2025006385A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel malaria vaccine comprising ama1 and ron2 antigens
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025051381A1 (en) 2023-09-08 2025-03-13 BioNTech SE Methods and compositions for localized expression of administered rna
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025106738A1 (en) 2023-11-15 2025-05-22 BioNTech SE Sars-cov-2 immunogenic compositions
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025151019A1 (ko) * 2024-01-12 2025-07-17 주식회사 루카에이아이셀 양이온성 리포좀 및 이를 이용한 rna 리포플렉스의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771706B2 (en) * 1999-07-15 2004-04-01 University Of British Columbia, The Methods and apparatus for preparation of lipid vesicles
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
WO2003049763A1 (en) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
US7008403B1 (en) 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
JP4987474B2 (ja) * 2003-06-04 2012-07-25 ジョージタウン・ユニバーシティ リポソーム複合体の安定性および使用期限を改良するための方法
EP1512393A1 (de) * 2003-09-08 2005-03-09 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
ES2549728T3 (es) * 2006-04-20 2015-11-02 Silence Therapeutics Gmbh Formulaciones de lipoplexo para la administración específica al endotelio vascular
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009111088A2 (en) * 2008-01-02 2009-09-11 The Johns Hopkins University Antitumor immunization by liposomal delivery of vaccine to the spleen
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
JP5823405B2 (ja) * 2009-11-04 2015-11-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 核酸含有脂質粒子および関連方法
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP3391877A1 (en) * 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
WO2012112730A2 (en) * 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
CN102144973A (zh) * 2011-03-31 2011-08-10 中国药科大学 一种优化的siRNA阳离子脂质体的处方组成
CN102727436A (zh) * 2011-04-15 2012-10-17 百奥迈科生物技术有限公司 核酸脂质体药物制剂
CA2853689C (en) * 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP2830593B1 (en) * 2012-03-26 2019-02-27 BioNTech RNA Pharmaceuticals GmbH Rna formulation for immunotherapy
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CN103194489B (zh) * 2013-03-26 2015-09-30 中国科学院过程工程研究所 新型阳离子脂质体核酸类药物制剂,及其制备方法和应用
RU2016109938A (ru) * 2013-08-21 2017-09-26 Куревак Аг Композиция и вакцина для лечения рака предстательной железы
WO2015043613A1 (en) * 2013-09-26 2015-04-02 Biontech Ag Particles comprising a shell with rna
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
EP3206400A4 (en) * 2014-10-06 2018-05-16 Sony Corporation Image processing device and method
JP6764870B2 (ja) * 2015-02-24 2020-10-07 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 連続フローマイクロ流体システム
CN107427791B (zh) * 2015-03-19 2021-05-14 康涅狄格大学 用于连续制造脂质体药物制剂的系统和方法
WO2016155809A1 (en) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
JP7738979B2 (ja) * 2016-11-10 2025-09-16 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
RU2022103533A (ru) 2017-10-20 2022-03-10 Бионтек Рна Фармасьютикалс Гмбх (Biontech Rna Pharmaceuticals Gmbh) Приготовление и хранение липосомальных РНК-составов, подходящих для терапии

Also Published As

Publication number Publication date
EP3697384A1 (en) 2020-08-26
KR20250024524A (ko) 2025-02-18
RU2020113577A3 (es) 2022-02-16
JP2021500324A (ja) 2021-01-07
AR113782A1 (es) 2020-06-10
BR112020007470A2 (pt) 2020-10-27
MX2024001218A (es) 2024-02-12
US11395799B2 (en) 2022-07-26
KR102762217B1 (ko) 2025-02-07
RU2020113577A (ru) 2021-11-22
US20200246267A1 (en) 2020-08-06
SG11202002579SA (en) 2020-05-28
KR20200100619A (ko) 2020-08-26
AU2023201185B2 (en) 2025-05-08
MX2024001210A (es) 2024-11-08
AU2023201185A1 (en) 2023-04-06
TW202146031A (zh) 2021-12-16
ZA202001675B (en) 2021-07-28
AU2018350846A1 (en) 2020-04-23
WO2019077053A1 (en) 2019-04-25
EP3858333A1 (en) 2021-08-04
CN114344486A (zh) 2022-04-15
TW201927288A (zh) 2019-07-16
CA3078292A1 (en) 2019-04-25
AU2018350846B2 (en) 2022-12-08
EP3858333B1 (en) 2025-11-26
JP2023052184A (ja) 2023-04-11
MX2020003413A (es) 2020-07-20
CN111246845A (zh) 2020-06-05
JP2025003984A (ja) 2025-01-14
CN114392233A (zh) 2022-04-26
US20210161818A1 (en) 2021-06-03
US12059498B2 (en) 2024-08-13
RU2022103533A (ru) 2022-03-10
US20250108008A1 (en) 2025-04-03
IL273852A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
AR127361A2 (es) Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
PH12020550051B1 (en) Glp-1 compositions and uses thereof
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
MX368894B (es) Composiciones para el cuidado bucal que comprenden haluros de aminoacidos y zinc.
CU20210081A7 (es) Composición de partículas de arn lipoplejo
AR108631A1 (es) Formulación de neurotoxinas
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
CL2017001605A1 (es) Composición farmacéutica que comprende plasminógeno y usos de este.
SA519410114B1 (ar) صيغ موضعية تحتوي على سيكلوسبورين واستخداماتها
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
NZ778977A (en) Therapeutic antibody formulation
MX2018014916A (es) Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
MX2022005317A (es) Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
EA201891337A2 (ru) Фармацевтическая композиция от нейропатической боли
MX2016012447A (es) Formulaciones de factor ix liofilizadas.
ZA202102816B (en) High concentration protein formulation
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
EA202092069A1 (ru) Композиции и способы лечения макулярной дистрофии
MY197491A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
PH12020551618A1 (en) Erenumab compositions and uses thereof